Literature DB >> 20217129

Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.

Hyun Chang1, Sun Young Rha, Hei-Cheul Jeung, Jae-Jun Jung, Tae Soo Kim, Ho Jeong Kwon, Byung Soo Kim, Hyun Cheol Chung.   

Abstract

PURPOSE: We evaluated the cytotoxic effects of combining suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, with taxanes in human gastric cancer cell lines and assessed the pre-treatment difference of gene expression to identify genes that could potentially mediate the cytotoxic response.
METHODS: Gastric cancer cell lines were treated with SAHA and paclitaxel or docetaxel, and the synergistic interaction between the drugs was evaluated in vitro using the combination index (CI) method. We performed significance analysis of microarray (SAM) to identify chemosensitivity-related genes in gastric cancer cell lines that were concomitantly treated with SAHA and taxane. We generated a correlation matrix between gene expression and CI values to identify genes whose expression correlated with a combined effect of taxanes and SAHA.
RESULTS: Combination treatment with taxane and SAHA had a synergistic cytotoxic effect against taxane-resistant gastric cancer cells. We identified 49 chemosensitivity-related genes via SAM analysis. Among them, nine common genes (SLIT2, REEP2, EFEMP2, CDC42SE1, FSD1, POU1F1, ZNF79, ETNK1, and DOCK5) were extracted from the subsequent correlation matrix analysis.
CONCLUSIONS: The combination of taxane and SAHA could be efficacious for the treatment of gastric cancer. The genes that were related to the synergistic response to taxane and SAHA could serve as surrogate biomarkers to predict the therapeutic response in gastric cancer patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20217129     DOI: 10.1007/s00432-010-0849-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  37 in total

1.  Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation.

Authors:  Wen Yue; Sanja Dacic; Quanhong Sun; Rodney Landreneau; Mingzhou Guo; Wei Zhou; Jill M Siegfried; Jian Yu; Lin Zhang
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

Review 2.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

Authors:  Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

Review 3.  Potential disease targets for drugs that disrupt protein-- protein interactions of Grb2 and Crk family adaptors.

Authors:  Stephan M Feller; Marc Lewitzky
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

4.  Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray.

Authors:  Satoshi Yamashita; Yoshimi Tsujino; Kazuki Moriguchi; Masae Tatematsu; Toshikazu Ushijima
Journal:  Cancer Sci       Date:  2006-01       Impact factor: 6.716

5.  An attempt for combining microarray data sets by adjusting gene expressions.

Authors:  Ki-Yeol Kim; Se Hyun Kim; Dong Hyuk Ki; Jaeheon Jeong; Ha Jin Jeong; Hei-Cheul Jeung; Hyun Cheol Chung; Sun Young Rha
Journal:  Cancer Res Treat       Date:  2007-06-30       Impact factor: 4.679

6.  Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling.

Authors:  Bekim Sadikovic; Maisa Yoshimoto; Susan Chilton-MacNeill; Paul Thorner; Jeremy A Squire; Maria Zielenska
Journal:  Hum Mol Genet       Date:  2009-03-13       Impact factor: 6.150

7.  Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism.

Authors:  Teresa Gómez Del Pulgar; Fátima Valdés-Mora; Eva Bandrés; Rosa Pérez-Palacios; Carolina Espina; Paloma Cejas; Miguel Angel García-Cabezas; Manuel Nistal; Enrique Casado; Manuel González-Barón; Jesús García-Foncillas; Juan Carlos Lacal
Journal:  Int J Oncol       Date:  2008-07       Impact factor: 5.650

8.  Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines.

Authors:  Marielle Dejligbjerg; Morten Grauslund; Ib Jarle Christensen; Jette Tjørnelund; Peter Buhl Jensen; Maxwell Sehested
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

9.  Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model.

Authors:  Akihiko Miyanaga; Akihiko Gemma; Rintaro Noro; Kiyoko Kataoka; Kuniko Matsuda; Michiya Nara; Tetsuya Okano; Masahiro Seike; Akinobu Yoshimura; Akiko Kawakami; Haruka Uesaka; Hiroki Nakae; Shoji Kudoh
Journal:  Mol Cancer Ther       Date:  2008-07-07       Impact factor: 6.261

10.  Expression profile of histone deacetylase 1 in gastric cancer tissues.

Authors:  J H Choi; H J Kwon; B I Yoon; J H Kim; S U Han; H J Joo; D Y Kim
Journal:  Jpn J Cancer Res       Date:  2001-12
View more
  16 in total

Review 1.  Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.

Authors:  K Ted Thurn; Scott Thomas; Amy Moore; Pamela N Munster
Journal:  Future Oncol       Date:  2011-02       Impact factor: 3.404

2.  Genome-wide identification of possible methylation markers chemosensitive to targeted regimens in colorectal cancers.

Authors:  Jin C Kim; Han C Lee; Dong H Cho; Eun Y Choi; Yoon K Cho; Ye J Ha; Pyong W Choi; Seon A Roh; Seon Y Kim; Yong S Kim
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-18       Impact factor: 4.553

3.  DOCK4 as a Potential Biomarker Associated with Immune Infiltration in Stomach Adenocarcinoma: A Database Analysis.

Authors:  Yi Lu; Jiaxi Yu; Qiuping Dong; Yan Du; Zheng Liang
Journal:  Int J Gen Med       Date:  2022-07-11

Review 4.  How to stomach an epigenetic insult: the gastric cancer epigenome.

Authors:  Nisha Padmanabhan; Toshikazu Ushijima; Patrick Tan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-17       Impact factor: 46.802

Review 5.  Epigenetic therapy in gastrointestinal cancer: the right combination.

Authors:  Eihab Abdelfatah; Zachary Kerner; Nainika Nanda; Nita Ahuja
Journal:  Therap Adv Gastroenterol       Date:  2016-05-01       Impact factor: 4.409

6.  Genetic variations using whole-exome sequencing might predict response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Authors:  In Hee Lee; Keunsoo Kang; Byung Woog Kang; Soo Jung Lee; Woo Kyun Bae; Jun Eul Hwang; Hye Jin Kim; Su Yeon Park; Jun Seok Park; Gyu Seog Choi; Jong Gwang Kim
Journal:  Med Oncol       Date:  2018-09-11       Impact factor: 3.064

Review 7.  Novel targeted agents for gastric cancer.

Authors:  Lian Liu; Ning Wu; Jin Li
Journal:  J Hematol Oncol       Date:  2012-06-18       Impact factor: 17.388

8.  Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer.

Authors:  Sofie Claerhout; Jae Yun Lim; Woonyoung Choi; Yun-Yong Park; Kyounghyun Kim; Sang-Bae Kim; Ju-Seog Lee; Gordon B Mills; Jae Yong Cho
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

Review 9.  Molecular targeted therapy for advanced gastric cancer.

Authors:  Jong Gwang Kim
Journal:  Korean J Intern Med       Date:  2013-02-27       Impact factor: 2.884

10.  Discovery analysis of TCGA data reveals association between germline genotype and survival in ovarian cancer patients.

Authors:  Rosemary Braun; Richard Finney; Chunhua Yan; Qing-Rong Chen; Ying Hu; Michael Edmonson; Daoud Meerzaman; Kenneth Buetow
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.